Skip to main content

PDS Biotechnology Corp

corporate_fare Company Profile

PDS Biotechnology Corp

PDSB·NASDAQ·Life Sciences·CIK 0001472091

PDS Biotechnology Corporation is a clinical-stage immunotherapy company that develops targeted cancer and infectious disease immunotherapies. The company's pipeline is based on its Versamune® T cell activator and Versamune® in combination with its interleukin 12 (IL-12) fused anti-body drug conjugate (ADC), PDS01ADC. Additionally, the company is developing the Infectimune® T cell-activator for infectious diseases. Versamune® immunotherapies and Versamune® in combination with PDS01ADC are being developed for oncology treatments. Infectimune® is being developed for preventive vaccines against infectious agents. When paired with an antigen, Versamune® and Infectimune® have been shown to induce, in-vivo, large quantities of high-quality, highly potent polyfunctional disease-specific CD4 helper and CD8 killer T cells. Infectimune® is also designed to promote the induction of disease-specific neutralizing antibodies. PDS01ADC is an investigational tumor targeting IL-12. In September 2024, the company announced updated data from its VERSATILE-002 Phase 2 clinical trial at the European Society for Medical Oncology (ESMO) Congress 2024. In October 2024, the company announced updated data from the IMMUNOCERV Phase 2 clinical trial evaluating PDS0101 with chemoradiation to treat locally advanced cervical cancer at the American Society for Radiation Oncology (ASTRO) annual meeting 2024.

PDS Biotechnology Corp (NASDAQ:PDSB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 38 items for PDSB at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-20, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for PDSB spans PRE 14A, 8-K, S-3, SCHEDULE 13D.

Recent high-impact activity:

  • PDS Biotech Seeks 1-for-10 to 1-for-35 Reverse Split to Hold Nasdaq Listing
  • PDS Biotech Posts Q3 Loss of $7.6M With $15.2M Cash and Zero Long-Term Debt
  • NantWorks Exercises PDS Biotech Warrants for $3.9M in Gross Proceeds
  • PDS Biotech Swaps Four Directors for Three Pharma Veterans, Leaves One Seat Open
  • PDS Biotech Registers 110M Shares for Resale, Including 50M Milestone Warrants

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$34.5M
Diluted EPS
-$0.74
Op. Cash Flow
-$27.75M
Free Cash Flow
-$27.75M
Operating Income
-$31.54M
Cash & Equivalents
$26.71M
Debt / Equity
0.00×
Shares Outstanding
54.88M sh
Source: 10-K · filed 2026-04-28 · accession 0001140361-26-017461

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 3,523,357 shares in PDSB as of the October 30, 2026 settlement, a 4.0% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 40.0% of PDSB volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)3,523,357 shares as of October 30, 2026
Change vs prior period▲ 4.0%
Days to cover1.00 at avg daily volume of 7,667,975
Daily short volume (FINRA facilities)40.0% of 1,993,544 shares on November 20, 2026
5-day average short volume44.3%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for PDSB, detected from its recent SEC filings · based on capital-structure filings through 2026-07-10.

1 recent capital raiseATM program2 shelf registrations

$50 Million At-The-Market (ATM) Offering Activated · Significant Potential Dilution

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with P →
$0.785 +0.98% today
52-week range · as of 2026-11-20 $0.1952 – $1.79
Market cap
$81.63M
Volume
2.9M (0.4× avg)
3-mo avg 6.5M
Live data · 2026-11-21 15:48 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed PDSB - Latest Insights

PDSB
Nov 20, 2026, 4:30 PM EST
Filing Type: PRE 14A
Importance Score:
7
Price at Filing: $0.7823
Real-time Price: $0.785 info
Change: +$0.0027 (+0.35%) info
Market Cap: $81.631M info
PDSB
Nov 13, 2026, 8:05 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.9822
Real-time Price: $0.785 info
Change: -$0.1972 (-20%) info
Market Cap: $81.631M info
PDSB
Nov 10, 2026, 8:05 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.08
Real-time Price: $0.785 info
Change: -$0.295 (-27%) info
Market Cap: $81.631M info
PDSB
Oct 20, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.9521
Real-time Price: $0.785 info
Change: -$0.1671 (-18%) info
Market Cap: $81.631M info
PDSB
Oct 14, 2026, 4:17 PM EDT
Filing Type: S-3
Importance Score:
7
Price at Filing: $1.41
Real-time Price: $0.785 info
Change: -$0.625 (-44%) info
Market Cap: $81.631M info
PDSB
Sep 22, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.8334
Real-time Price: $0.785 info
Change: -$0.0484 (-6%) info
Market Cap: $81.631M info
PDSB
Sep 22, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.8334
Real-time Price: $0.785 info
Change: -$0.0484 (-6%) info
Market Cap: $81.631M info
PDSB
Sep 21, 2026, 9:56 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
Price at Filing: $0.8311
Real-time Price: $0.785 info
Change: -$0.0461 (-6%) info
Market Cap: $81.631M info
PDSB
Sep 14, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.3785
Real-time Price: $0.785 info
Change: +$0.4065 (+107%) info
Market Cap: $81.631M info
PDSB
Sep 08, 2026, 8:35 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.410
Real-time Price: $0.785 info
Change: +$0.375 (+91%) info
Market Cap: $81.631M info
PDSB
Sep 04, 2026, 5:25 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.2232
Real-time Price: $0.785 info
Change: +$0.5618 (+252%) info
Market Cap: $81.631M info
PDSB
Aug 25, 2026, 4:08 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.2201
Real-time Price: $0.785 info
Change: +$0.5649 (+257%) info
Market Cap: $81.631M info
PDSB
Aug 19, 2026, 4:52 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.2047
Real-time Price: $0.785 info
Change: +$0.5803 (+283%) info
Market Cap: $81.631M info
PDSB
Aug 13, 2026, 4:20 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.2372
Real-time Price: $0.785 info
Change: +$0.5478 (+231%) info
Market Cap: $81.631M info
PDSB
Aug 13, 2026, 8:39 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $0.2395
Real-time Price: $0.785 info
Change: +$0.5455 (+228%) info
Market Cap: $81.631M info
PDSB
Aug 13, 2026, 8:35 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.2412
Real-time Price: $0.785 info
Change: +$0.5438 (+225%) info
Market Cap: $81.631M info
PDSB
Aug 11, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.750
Real-time Price: $0.785 info
Change: +$0.035 (+5%) info
Market Cap: $81.631M info
PDSB
Aug 11, 2026, 8:25 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.760
Real-time Price: $0.785 info
Change: +$0.025 (+3%) info
Market Cap: $81.631M info
PDSB
Jul 31, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.6861
Real-time Price: $0.785 info
Change: +$0.0989 (+14%) info
Market Cap: $81.631M info
PDSB
Jul 10, 2026, 4:30 PM EDT
Filing Type: S-3
Importance Score:
7
Price at Filing: $0.7594
Real-time Price: $0.785 info
Change: +$0.0256 (+3%) info
Market Cap: $81.631M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets